PF-05089771

PF-05089771 is a selective, small-molecule Na v 1.7 and Na v 1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

PF-05089771 is a selective, small-molecule Na v 1.7 and Na v 1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic. As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1314741879 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.